Effects of ozone therapy on haemostatic and oxidative stress index in coronary artery disease.
Coronary artery disease (CAD) is the most common cause of sudden death, and death of people over 20 years of age. Because ozone therapy can activate the antioxidant system and improve blood circulation and oxygen delivery to tissue, the aim of this study was to investigate the therapeutic efficacy of ozone in patients with CAD, treated with antithrombotic therapy, Aspirin and policosanol. A randomized controlled clinical trial was performed with 53 patients divided into two groups: one (n=27) treated with antithrombotic therapy and other (n=26) treated with antithrombotic therapy plus rectal insufflation of O(3). A parallel group (n=50) age and gender matched was used as reference for the experimental variables. The efficacy of the treatments was evaluated by comparing hemostatic indexes and biochemical markers of oxidative stress in both groups after 20 day of treatment. Ozone treatment significantly (P<0.001) improved prothrombin time when compared to the antithrombotic therapy only group, without modifying bleeding time. Combination antithrombotic therapy+O(3) improved the antioxidant status of patients reducing biomarkers of protein and lipid oxidation, enhancing total antioxidant status and modulating the level of superoxide dismutase and catalase with a 57% and 32% reduction in superoxide dismutase and catalase activities respectively, moving the redox environment to a status of low production of O(2)(•-) with an increase in H(2)O(2) detoxification. No side effects were observed. These results show that medical ozone treatment could be a complementary therapy in the treatment of CAD and its complications.
Medinat srl Clinic, Via Fazioli 22, 60021 Camerano, Italy. gregorcuba@yahoo.it
Gregorio
G
Martínez-Sánchez
Livan
L
Delgado-Roche
Arquímides
A
Díaz-Batista
Gema
G
Pérez-Davison
Lamberto
L
Re
D000368:Aged; D000369:Aged, 80 and over; D000975:Antioxidants / Q000378:metabolism; D001241:Aspirin / Q000627:therapeutic use; D015415:Biomarkers / Q000378:metabolism; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology*; D005233:Fatty Alcohols / Q000627:therapeutic use; D005260:Female; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects*; D010126:Ozone / Q000494:pharmacology* / Q000627:therapeutic use; D017382:Reactive Oxygen Species / Q000378:metabolism
D000975:Antioxidants; D015415:Biomarkers; D005233:Fatty Alcohols; D017382:Reactive Oxygen Species; D010126:Ozone; C044309:1-octacosanol; D001241:Aspirin